Tuesday, September 4, 2012

LIST OF KEY PRESENTATIONS AT EASD

Tuesday 2/10

Insulin

1) Eli Lilly: ‘Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism’ (OP04: presentation 19, 10:45-12:15, Heubner Hall)

2) Eli Lilly: 2 posters on Humalog-PEG long-acting insulin LY2605541 (PS073: posters 913 & 914, 12:30-13:30)

3) Halozymes: ‘Human hyaluronidase + rapid analogue insulin improves PPG control in T2D compared to lispro alone’ (PS073: poster 908, 12:30-13:30)

4)Eli Lilly: 5 posters on Humalog-PEG long-acting insulin LY2605541 (PS074: posters 916-919 & 922, 13:45-14:45)

5) Halozymes: ‘Human hyaluronidase + rapid analogue insulin improves PPG glycaemic control in T1D compared to lispro alone’ (OP07: presentation 41, 15:00-16:30, LangerHans Hall)

6) Eli Lilly: ‘Humalog-PEG long-acting insulin LY2605541: Leveraging hydrodynamic size to develop a new basal insulin’ (OP07: presentation 42, 15:00-16:30, LangerHans Hall)

Insulin-GLP-1 loose combinations

7)Incretin based therapies’ (PS055, 12:30-13:30)

GLP-1

1)BMS/AZ: ‘Exenatide once weekly resulted in sustained improvement in glycaemic control with weight loss through four years’ (OP01: presentation 4, 10:45-12:15, Langerhans Hall)

OAD’s


1)BMS/AZ: 6 posters on dapagliflozin (PS056: posters 743-748, 13:45-14:45)


Wednesday 3/10

Insulin

1) Eli Lilly: ‘In vitro characterization of novel basal insulin LY2605541: reduced mitogenicity and IGF-IR binding’ (OP20: presentation 120, 14:30-16:00, Virchow Hall)

GLP-1

1) Sanofi: 9 posters on lixisenatide (PS063: posters 807-815, 12:00-13:00)

· BMS/AZ: ‘PK and PD of a new exenatide formulation, exenatide suspension’ (PS064: poster 825, 13:15-14:15)

OAD’s


1) BMS/AZ: 10 posters on dapagliflozin (PS057: posters 749-758, 12:00-13:00)

2) J&J: 8 posters on canagliflozin (PS058: posters 759-766, 13:15-14:15)

3) Merck: ‘Effect of MK-3102, a novel once-weekly DPP-4 inhibitor, over 12 weeks in patients with T2D’ (OP19: presentation 110, 14:30-16:00, Langerhans Hall)



Thursday 4/10

Insulin

1) Insulin therapy: clinical perspectives’ (PS077, 12:00-13:00)

GLP-1

1) GSK: ‘Once weekly GLP-1 receptor agonist albiglutide vs prandial lispro added to basal glargine in T2D’ (PS036: poster 581, 13:15-14:15)

OAD’s
1) BI/Eli Lilly: 3 posters on empagliflozin (PS059: posters 769-771, 12:00-13:00)

2)BMS/AZ: 1 poster on dapagliflozin (PS059: poster 777, 12:00-13:00)



Friday 5/10

OAD’s

1) BMS/AZ: ‘Dapagliflozin does not impact renal function in patients with type 2 diabetes’ (OP43: presentation 242, 11:00-12:00)

2) J&J: 2 oral presentations on canagliflozin, incl: ‘Efficacy and safety of canagliflozin, compared with sitagliptin in patients with T2D’ (OP43: presentations 243 & 244, 11:00-12:00)